Q4 2025 Orexo AB Earnings Call Transcript
Key Points
- Orexo AB (ORXOF) successfully completed the divestment of ZUBSOLV to Dexcel Pharma, strengthening its financial position.
- The company ended 2025 with SEK912 million in cash, an increase from the previous year, providing a strong financial foundation.
- Orexo AB (ORXOF) is focusing on its core AmorphOX technology platform, which is expected to drive future growth and innovation.
- The transition phase with Dexcel includes reimbursement for services provided by Orexo, ensuring continued revenue streams.
- Orexo AB (ORXOF) has several promising R&D projects in the pipeline, including OX640 and IZIPRY, with plans for clinical trials and regulatory filings in 2026.
- The divestment of ZUBSOLV has led to a complex financial restructuring, making it challenging to analyze continued operations.
- Orexo AB (ORXOF) faces ongoing restructuring costs during the transition period, impacting short-term financial performance.
- The company is still dealing with a Department of Justice investigation, which could pose legal and financial risks.
- There is uncertainty regarding the timeline for clinical trials and regulatory approvals, affecting R&D expense projections.
- Orexo AB (ORXOF) needs to secure partnerships for its pipeline projects to ensure long-term sustainability and reduce financial risk.
Welcome to conference call. (Operator Instructions)
Now I will hand the conference over to the speakers. Please go ahead.
Good afternoon, everyone, and good morning to those of you dialing in from the US. I'm Nikolaj Sorensen, and I'm here together with Orexo's CEO (sic - see company's Leadership page, "CFO"); Fredrik Jarrsten. So today, we're going to go through our fourth quarter and year-end results. We will provide a business update. This time, it will be a little special because of the transaction we just completed, as most of you are probably aware of, and the divestment of ZUBSOLV.
So we will have a lot of focus on the transaction and the implications on the organization and the same for the financials. The financials have a significant impact from the transaction, of course, but also the way that the financials are structured makes it a little more difficult than usual to analyze and understand the implications for the company going forward and even the performance in the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
